Steve holds a PhD in Biochemistry from the Faculty of Medicine at the University of Toronto, Canada. He worked as a medical scientist for 18 years, within both industry and academia, where his research focused on the discovery of new medicines to treat inflammatory disorders and infectious diseases. Steve recently stepped away from the lab and into science communications, where he’s helping make medical science information more accessible for everyone.
The U.S. Food and Drug Administration (FDA) has granted its Rare Pediatric Disease designation to Mateon Therapeutics’ OXi-4503 (combretastatin A1-diphosphate, CA1P) for the treatment of children and teens with acute ... Read more
The U.S. Food and Drug Administration (FDA) has granted Aptose Biosciences an investigational new drug (IND) allowance that will let the company begin a human Phase 1a/b clinical study of ... Read more